Fierce Pharma
NOVEMBER 7, 2023
Pfizer’s $3.5 billion cost-savings drive has made its way overseas. | The layoffs at Pfizer's Newbridge, Kildare, manufacturing site are the latest in the company's effort to save $3.5 billion by 2024 amid declining demand for its COVID-19 products.
MedCity News
NOVEMBER 7, 2023
The Federal Trade Commission says more than 100 patents from 10 biopharma companies are improperly listed in the FDA’s official publication of approved products. Such listings delay generic competition, which reduces consumer choice and keeps prices high, the regulator said.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
NOVEMBER 7, 2023
Pharma, you were warned. | Only two months after the Federal Trade Commission said it was eying a crackdown on improper patents listed by the FDA, the agency has filed challenges against more than 100 patents in the agency's Orange Book. The companies have 30 days to respond.
MedCity News
NOVEMBER 7, 2023
My phone chimed with a notification, signaling the availability of a new CT test result in my online health portal. “Multiple bilateral pulmonary nodules measuring up to 8mm. May represent metastatic disease.” This was several weeks after my very first mammogram–which I underwent shortly after my 40th birthday–detected an anomaly on my left breast. I soon learned I had what are called “dense” breasts, which means I have compact breast tissue and typical imaging isn’t the best screening for me.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
NOVEMBER 7, 2023
There might just be a silver lining for Johnson & Johnson in the FDA's recent approval of Amgen’s Stelara biosimilar. | There might just be a silver lining for Johnson & Jonhson in the FDA's recent approval of Amgen’s Stelara biosimilar. That’s because the coming entry of a cheaper copycat presents J&J with an opportunity to elude Medicare price negotiations outlined in the Inflation Reduction Act.
Copyright Clearance Center
NOVEMBER 7, 2023
November 7, 2023 – Danvers, Mass. – CCC , a pioneer in voluntary collective licensing, advancing copyright, accelerating knowledge, and powering innovation, announces Clinical Trial Registries, a new data connector for customers of the cloud-based software solution RightFind Navigate. The new data connector provides access to aggregated data from seven global clinical trial registries within a single personalized discovery tool that enables knowledge workers to find the latest clinical trial dat
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
NOVEMBER 7, 2023
Ventyx Biosciences is stopping work on its lead drug candidate in plaque psoriasis and psoriatic arthritis. Despite achieving the goals of its Phase 2 test in psoriasis, the results are short of those achieved by big pharmaceutical companies with molecules that address the same target.
Fierce Pharma
NOVEMBER 7, 2023
Two long-awaited treatments for sickle cell disease (SCD) are on the docket for FDA decisions next month. Vertex and CRISPR Therapeutics are up first with a Dec. | Two long-awaited treatments for sickle cell disease (SCD) are on the docket for FDA decisions next month. One potential advantage for bluebird, giving the timing, could be a chance to view its rival's pricing before deciding itself.
European Pharmaceutical Review
NOVEMBER 7, 2023
Positive results for a combination treatment using the first Fc-silent investigational monoclonal antibody in pivotal clinical trials that is designed to block and bind to the T-cell immunoreceptor with Ig and ITIM domains (TIGIT), have been announced. The treatment is being evaluated in patients with upper GI adenocarcinomas. Domvanalimab plus the antibody zimberelimab and chemotherapy showed encouraging overall response rate and six-month progression-free survival (PFS) rate results in a preli
Fierce Pharma
NOVEMBER 7, 2023
Armed with dwarfism med Voxzogo and hemophilia A gene therapy Roctavian, BioMarin Pharmaceutical recently turned a corner into profitability after many years operating at a loss. | Armed with dwarfism med Voxzogo and hemophilia A gene therapy Roctavian, BioMarin recently turned a corner into profitability after many years operating at a loss. Now, the drugmaker has reportedly garnered the attention of activist investor Elliott Management.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PharmExec
NOVEMBER 7, 2023
Due to a higher than anticipated demand, Sanofi is carefully managing distribution of 50 mg doses of Beyfortus in the private market to fulfill existing orders and provide equitable access to remaining doses for the vaccine that protects infants against respiratory syncytial virus.
Fierce Pharma
NOVEMBER 7, 2023
Before Sage and Biogen’s Zurzuvae (zuranolone) won approval from the FDA for postpartum depression (PPD) in August, the companies had said that the highly anticipated first-in-class treatment would | Before Sage and Biogen’s Zurvuvae was approved by the FDA for postpartum depression in August, the companies had said that the highly anticipated treatment would be available for less than $10,000.
MedCity News
NOVEMBER 7, 2023
Baylor Medicine teamed up with Luna to launch a program expanding access to in-home physical therapy for patients in the Houston area. Luna, a provider of in-home physical therapy, has similar partnerships with more than two dozen health systems. These partnerships help health systems expand access to care and increase their geographic coverage across their markets, said Palak Shah, Luna’s co-founder.
Fierce Pharma
NOVEMBER 7, 2023
WuXi's bioconjugation spinoff is set to break free onto the Hong Kong Stock Exchange this month, with plans to funnel hundreds of millions of dollars in proceeds back into its Asian manufacturing n | WuXi's bioconjugation spinoff is set to break free onto the Hong Kong Stock Exchange this month, with plans to funnel hundreds of millions of dollars in proceeds back into its Asian manufacturing network.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
MedCity News
NOVEMBER 7, 2023
Perhaps more of us would find greater joy and fulfillment at work, if we embraced the idea of being a beginner and starting anew. The most fulfilling path in the 21st century isn’t necessarily a straight line.
European Pharmaceutical Review
NOVEMBER 7, 2023
It has been more than three months since the Unified Patent Court (UPC) and the European patent with unitary effect (unitary patent) came into full force on 1 June 2023, adding a new layer of options to the existing European patent system of national courts and European patents. The unitary patent is a new, single pan-European right protecting an invention, which prohibits anyone but the owner or their licensee from using that invention in all participating EU Member States.
PharmaTech
NOVEMBER 7, 2023
Matthew Lauber, senior director—Cell and Gene Therapy, Consumables & Lab Automation, at Waters Corporation discusses the analytical and downstream purification challenges of oligonucleotides.
MedCity News
NOVEMBER 7, 2023
CMS proposed a new rule that would set a flat amount — $632 — that MA plans can pay agents and brokers when they help enroll a person into any MA plan. The proposed rule also addresses behavioral health access and prior authorization.
Pharmaceutical Commerce
NOVEMBER 7, 2023
Conference session discusses the drivers, practical considerations, success factors, and landscape for next-generation pharmacy innovation.
MedCity News
NOVEMBER 7, 2023
Covera Health has finalized its acquisition of CoRead, the companies announced last week but did not disclose the terms of the deal. Covera also announced that it raised up to $50 million in additional Series C funding led by Insight Partners.
PharmExec
NOVEMBER 7, 2023
Exagamglogene autotemcel (Exa-Cel) was assigned a Prescription Drug User Fee Act action date of December 8, 2023, for the treatment of sickle cell disease.
Pharmaceutical Commerce
NOVEMBER 7, 2023
Bill Roth provides insight as to how where chief commercial officers and access leaders can plan for a profitable product lifecycle.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
PharmExec
NOVEMBER 7, 2023
House Committee on Oversight and Accountability request documents on agency’s drug shortage mitigation strategies.
Clarivate
NOVEMBER 7, 2023
Generative AI presents enormous opportunities to transform how scientific and scholarly research is carried out. Faced with the pressure to publish, a more complex research environment to navigate, and growing administrative demands, researchers need better tools available to them. To meet these challenges, Clarivate is developing cutting-edge AI technology that will remove roadblocks in the research and publishing process and ultimately contribute to the betterment of research.
pharmaphorum
NOVEMBER 7, 2023
BioNTech flashes the cash, adding tumour drug in $1bn deal Phil.
Clarivate
NOVEMBER 7, 2023
What is the impact when IP departments are regularly asked to “do more with less”? Employees may feel that they are paying the price and burnout is on the rise. Instead, with thoughtful evaluation, IP legal teams can find areas of efficiency to work smarter with less. IP legal teams continue to face a universal business challenge: how to do more with less.
pharmaphorum
NOVEMBER 7, 2023
Generic breast cancer drug cleared for prevention in England Phil.
PharmaTimes
NOVEMBER 7, 2023
Doctors will use the service to track signs of deterioration in paediatric patients - News - PharmaTimes
pharmaphorum
NOVEMBER 7, 2023
CARGO eyes $300m IPO against lacklustre listings backdrop Phil.
PharmaTimes
NOVEMBER 7, 2023
Lung cancer is currently the leading cause of cancer deaths in the UK - News - PharmaTimes
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
300 
Let's personalize your content